A Mixed Methods Study of Chronic Kidney Disease (CKD) Self-Management

慢性肾脏病 (CKD) 自我管理的混合方法研究

基本信息

批准号：
10089437
负责人：
Sarah Jeanne Schrauben
金额：
$ 19.49万
依托单位：
UNIVERSITY OF PENNSYLVANIA
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-04-03 至 2024-01-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10089437
关键词：
Address Adherence Adoption Affect Age Area Award Behavior Biometry Blood Glucose Blood Pressure Monitors Cardiovascular Diseases Characteristics Chronic Kidney Failure Chronic Kidney Insufficiency Clinical Clinical Management Clinical Practice Guideline Clinical Trials Clinical Trials Design Cohort Studies Data Data Analyses Development Dialysis procedure Disease Disease Management Disease Outcome Disease Progression Economic Burden Education End stage renal failure Environment Epidemic Epidemiology Evaluation Feedback Fellowship Funding Grant Guidelines Health Health Technology Health behavior Hypertension Individual Intervention Intervention Studies Intervention Trial Interview Investigation Kidney Longevity Master&apos s Degree Mentored Patient-Oriented Research Career Development Award Mentorship Methods Nature Obesity Outcome Participant Patient Outcomes Assessments Patient Preferences Patients Pennsylvania Persons Physical activity Population Positioning Attribute Postdoctoral Fellow Predictive Factor Publishing Recommendation Research Research Design Research Methodology Research Personnel Research Priority Risk Science Self Management Statistical Data Interpretation Structure Syndrome Technology Testing Time Tobacco Training United States National Institutes of Health Universities Work approach behavior career career development clinical epidemiology cohort comorbidity cost cost effective design experience feasibility trial health economics health literacy healthy lifestyle implementation science improved mHealth multidisciplinary novel strategies patient engagement patient oriented patient oriented research pilot trial prevent programs prototype psychosocial recruit self-management program skills theories therapy design therapy development uptake usability

项目摘要

Project summary In late 2019, COVID-19, a disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) emerged in Wuhan, China and has rapidly impacted almost all countries around the world. Officially declared a global pandemic by the WHO, COVID-19 is a worldwide emergency and by million United with directly , current in vitro model platforms are so distinct from human infection that they may not capture key components of viral infection or virus-host interactions. May 29, 2020, over 5.8 COVID-19 cases were reported with over 360,000 deaths globally. Although originating in China the States has emerged as an epicenter of this pandemic with over 1.75 million COVID-19 cases reported over 103,000 deaths. Unfortunately there is no vaccine that can prevent SARS-CoV-2 infection or robust activing antivirals that can mitigate infection or alter disease progression. Moreover Given this local, national, and global emergency our near-term goal is on the development of novel and robust experimental cell culture models, virological tools, and to identify novel therapeutics for SARS-CoV-2 treatment. Our long-term goal is to elucidate the complex interactions and mechanisms underlying SARS-CoV-2 infection and host response. Given that our institution has been at the center of the COVID-19 pandemic here in the U.S. we have generated a wide database of clinical data that has revealed that a high prevalence of initial COVID- 19 presentations are with GI manifestations with over one-half of patients noted to have biochemical evidence of liver injury at presentation. The impact of SARS-CoV-2 infection on hepatocellular and cholangiocyte function remains unclear. To address these knowledge gaps we have generated several novel technologies and have assembled a robust team with complimentary expertise in stem cell biology, tissue engineering and virology, chemical screening and stem cell biology, and in virology/BSL3 expertise. We aim to identify drug candidates that impact SARS-CoV-2 viral infection while we evaluate host-virus interactions. Our work is urgently needed given the impacts SARS-CoV-2 has had on our local, national, and global communities and its potential impact on millions of people who already, or will in the future will develop COVID19 infection by shedding light on mechanisms, molecular targets, and potential drugs that could lead directly to the development of new antiviral treatments and therapies.

项目概要 2019 年底，COVID-19，一种由严重急性呼吸综合征冠状病毒 2 型（SARS- CoV-2）出现在中国武汉，并迅速影响了世界上几乎所有国家。正式世界卫生组织 (WHO) 宣布新冠肺炎 (COVID-19) 为全球大流行病，属于全球紧急情况，目前的体外模型平台与人类感染截然不同，以至于它们可能无法捕获病毒感染或病毒与宿主相互作用的关键组成部分。截至 2020 年 5 月 29 日，全球报告了超过 5.8 例 COVID-19 病例，死亡人数超过 36 万人。尽管起源于中国，但美国已成为这一流行病的震中，报告了超过 175 万例 COVID-19 病例超过103,000人死亡。不幸的是，没有疫苗可以预防 SARS-CoV-2 感染，也没有有效的疫苗。激活抗病毒药物可以减轻感染或改变疾病进展。而且鉴于这一地方、国家和全球紧急情况，我们的近期目标是开发新颖且强大的实验细胞培养模型、病毒学工具，并确定治疗 SARS-CoV-2 的新疗法。我们的长期目标是阐明 SARS-CoV-2 感染背后的复杂相互作用和机制以及主持人的回应。鉴于我们的机构一直处于美国 COVID-19 大流行的中心。我们已经生成了一个广泛的临床数据数据库，这些数据表明，最初的新冠病毒感染率很高， 19 例报告有胃肠道表现，其中超过一半的患者有生化证据就诊时有肝损伤。 SARS-CoV-2感染对肝细胞和胆管细胞的影响功能仍不清楚。为了解决这些知识差距，我们开发了几种新技术并组建了一支强大的团队，在干细胞生物学、组织工程和病毒学、化学筛选和干细胞生物学，以及病毒学/BSL3 专业知识。我们的目标是识别药物在我们评估宿主与病毒相互作用时影响 SARS-CoV-2 病毒感染的候选药物。鉴于 SARS-CoV-2 对我们地方、国家和全球产生的影响，我们的工作刻不容缓社区及其对数百万人的潜在影响，这些人已经或将来会发展通过揭示可能导致新冠病毒感染的机制、分子靶标和潜在药物直接促进新的抗病毒治疗和疗法的开发。